E-LIB Suche - Ergebnisse für: Park, Keunchil

1

Plain language summary of PAPILLON: amivantamab plus chemot..:

Sabari, Joshua K ; Girard, Nicolas ; Mansfield, Aaron S...
Future Oncology. , 2024

Link: https://doi.org/10.1080/..

2

Comprehensive analysis of transcription factor-based molecu..:

Park, Sehhoon ; Hong, Tae Hee ; Hwang, Soohyun...
eBioMedicine. 102 (2024) - p. 105062 , 2024

Link: https://doi.org/10.1016/..

3

Real-World Efficacy and Safety of Amivantamab for EGFR-Muta..:

Wang, Kaiwen ; Du, Robyn ; Myall, Nathaniel J....
Journal of Thoracic Oncology. 19 (2024) 3 - p. 500-506 , 2024

Link: https://doi.org/10.1016/..

4

A brief report on stable disease among amivantamab-treated ..:

Girard, Nicolas ; Park, Keunchil ; Lee, Se-Hoon...
Cancer Treatment and Research Communications. 40 (2024) - p. 100832 , 2024

Link: https://doi.org/10.1016/..

5

Biomarker-directed targeted therapy plus durvalumab in adva..:

Besse, Benjamin ; Pons-Tostivint, Elvire ; Park, Keunchil...
Nature Medicine. 30 (2024) 3 - p. 716-729 , 2024

Link: https://doi.org/10.1038/..

6

Avelumab Versus Platinum-Based Doublet Chemotherapy as Firs..:

Reck, Martin ; Barlesi, Fabrice ; Yang, James Chih-Hsin...
Journal of Thoracic Oncology. 19 (2024) 2 - p. 297-313 , 2024

Link: https://doi.org/10.1016/..

7

Management of infusion-related reactions (IRRs) in patients..:

Park, Keunchil ; Sabari, Joshua K. ; Haura, Eric B....
Lung Cancer. 178 (2023) - p. 166-171 , 2023

Link: https://doi.org/10.1016/..

8

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Tre..:

Kim, Dong-Wan ; Kim, Sang-We ; Camidge, D. Ross...
Journal of Thoracic Oncology. 18 (2023) 5 - p. 650-656 , 2023

Link: https://doi.org/10.1016/..

9

Expanded Access Program Pralsetinib in Advanced Non–Small C..:

Jeon, Youngkyung ; Jung, Hyun Ae ; Park, Sehhoon...
Cancer Research and Treatment. 55 (2023) 4 - p. 1144-1151 , 2023

Link: https://doi.org/10.4143/..

10

Whole-Section Landscape Analysis of Molecular Subtypes in C..:

Hwang, Soohyun ; Hong, Tae Hee ; Kim, Hong Kwan...
Modern Pathology. 36 (2023) 7 - p. 100184 , 2023

Link: https://doi.org/10.1016/..

11

A Phase 2 Study of Palbociclib for Recurrent or Refractory ..:

Jung, Hyun Ae ; Kim, Miso ; Kim, Hae Su...
Journal of Thoracic Oncology. 18 (2023) 2 - p. 223-231 , 2023

Link: https://doi.org/10.1016/..

12

ICGC-ARGO precision medicine: an update on targeted therapy..:

Kotani, Daisuke ; Nakamura, Yoshiaki ; Fujisawa, Takao...
The Lancet Oncology. 24 (2023) 1 - p. 20-21 , 2023

Link: https://doi.org/10.1016/..

13

Efficacy and Safety of Ceritinib 450 mg/day with Food and 7..:

Cho, Byoung Chul ; Kim, Dong-Wan ; Batra, Ullas...
Cancer Research and Treatment. 55 (2023) 1 - p. 83-93 , 2023

Link: https://doi.org/10.4143/..

14

Phase II Trial of Combined Durvalumab Plus Tremelimumab wit..:

Kim, Hana ; Park, Sehhoon ; Jung, Hyun Ae...
Cancer Research and Treatment. 55 (2023) 4 - p. 1104-1112 , 2023

Link: https://doi.org/10.4143/..

15

Biomarker‐driven phase 2 umbrella trial: Clinical efficacy ..:

Park, Sehhoon ; Kim, Yu Jung ; Min, Young Joo...
Cancer. 130 (2023) 4 - p. 541-552 , 2023

Link: https://doi.org/10.1002/..